By Billy Candra 
A groundbreaking new study, known as WISDOM (Women Informed to Screen Depending On Measures of Risk), suggests a transformative shift in breast cancer screening practices, advocating for a personalized, risk-based approach over the long-standing universal age-based recommendations. The research indicates that tailoring screening frequency to a woman’s individual risk profile is not only safer but also more effective, potentially reducing the incidence of advanced cancers while optimizing resource allocation and patient care. Published on December 12 in the prestigious journal JAMA and simultaneously presented at the San Antonio Breast Cancer Symposium, these findings emanate from the initial phase of the WISDOM study, which analyzed data from 46,000 women across the United States, with UCSF serving as the coordinating center.
The Evolving Landscape of Breast Cancer Screening
Breast cancer remains the most frequently diagnosed cancer among women in the United States, excluding non-melanoma skin cancers. According to the American Cancer Society, approximately 1 in 8 women will develop invasive breast cancer in their lifetime. Early detection through screening has been a cornerstone of efforts to reduce breast cancer mortality since the widespread adoption of mammography in the 1980s. For decades, screening guidelines largely operated under the assumption that most women faced a similar baseline risk, with age being the primary determinant for when and how often screening should occur. This "one-size-fits-all" model, championed by organizations like the American Cancer Society (ACS) and the U.S. Preventive Services Task Force (USPSTF), typically recommends biennial or annual mammograms for women starting in their 40s or 50s.
However, the efficacy and implementation of these universal guidelines have been subject to ongoing debate and refinement. Critics have pointed to potential drawbacks, including overdiagnosis (the detection of cancers that would never have caused harm), false positives leading to unnecessary biopsies and anxiety, and the cumulative effects of radiation exposure. Moreover, research has consistently demonstrated that an individual’s risk of developing breast cancer can vary dramatically based on a complex interplay of genetic predispositions, lifestyle choices, reproductive history, and breast density, factors largely unaddressed by age-based screening alone. The WISDOM study directly confronts these limitations, proposing a sophisticated model that incorporates a comprehensive risk assessment to guide screening decisions.
Genesis and Methodology of the WISDOM Study
The WISDOM study, which commenced enrollment in 2016, was designed as a direct comparison between the traditional annual mammography approach and a novel screening strategy based on individual risk assessment. Its primary objective was to determine if a personalized screening regimen could achieve similar or superior outcomes in terms of cancer detection and patient safety, specifically avoiding an increase in late-stage cancer diagnoses, while reducing potential harms associated with over-screening.
Researchers employed well-validated risk models to categorize participants into four distinct groups. This comprehensive risk evaluation extended far beyond age, integrating a multitude of factors:
- Age: While not the sole determinant, age remained a foundational component.
- Genetic Information: Crucially, the study incorporated genetic testing for known pathogenic variants (like BRCA1 and BRCA2) and also utilized polygenic risk scores (PRS), which assess the cumulative effect of many common genetic variations, each having a small individual impact on risk.
- Lifestyle Factors: Elements such as diet, physical activity levels, alcohol consumption, and body mass index (BMI) were considered.
- Health History: Personal and family history of breast cancer, as well as other relevant medical conditions, contributed to the risk profile.
- Breast Density: A significant risk factor, higher breast density can also obscure cancers on mammograms, making it a critical component of risk assessment.
Based on these comprehensive evaluations, participants received tailored screening recommendations:
- Lowest Risk Group (26% of participants): Advised to delay routine screening until age 50 or until an algorithm indicated their individual risk had naturally elevated to that of a typical 50-year-old woman. This group represents a significant portion of women who might be undergoing unnecessary early or frequent screening under current guidelines.
- Average Risk Group (62% of participants): Recommended to undergo screening every two years, aligning with some current biennial recommendations for older age groups, but applied here based on individual risk rather than just age.
- Elevated Risk Group (8% of participants): Advised to receive annual mammograms, similar to current recommendations for women with higher-than-average risk.
- Highest Risk Group (2% of participants): This cohort received the most intensive screening, advised to undergo screening twice a year, alternating between mammography and magnetic resonance imaging (MRI), regardless of age. MRI is known for its higher sensitivity in detecting cancers, particularly in dense breasts or high-risk individuals.
Importantly, the study found no evidence that the personalized screening approach led to a higher rate of late-stage cancer diagnoses. This critical finding underscores the safety and efficacy of the risk-based strategy. Furthermore, the study noted strong participant acceptance: among women who chose not to be randomized into the study arms but joined an observational group, a remarkable 89% opted for the risk-based screening strategy, suggesting a clear preference for individualized care when given the choice.
Key Findings and Innovations Driving the Paradigm Shift
The WISDOM study has yielded several profound insights that challenge conventional wisdom and pave the way for a new era in breast cancer prevention and detection.
One of the most striking revelations concerns the integration of genetic testing. Traditionally, genetic testing for breast cancer susceptibility genes like BRCA1 and BRCA2 has been reserved for women with a strong family history of the disease or specific demographic criteria. The WISDOM study offered genetic testing to all participants, regardless of family history, leading to a significant discovery: 30% of women who tested positive for a genetic variant linked to higher breast cancer risk reported no family history of the disease. Under current clinical guidelines, these women would likely not have qualified for genetic testing and would have remained unaware of their heightened risk, potentially missing opportunities for earlier or more intensive screening and prevention. This finding alone highlights a critical gap in current screening paradigms and underscores the value of universal genetic screening within a comprehensive risk assessment framework.
Beyond well-known pathogenic variants, the study also pioneered the broader application of polygenic risk scores (PRS). PRS combines information from hundreds or thousands of common genetic variants, each contributing a small amount to an individual’s overall risk. This sophisticated approach significantly improved the precision of risk predictions, leading to 12% to 14% of participants being reassigned to a different risk category than they would have been based on traditional factors alone. This level of refinement allows for a much more nuanced and accurate understanding of individual risk.
The personalized approach extended beyond just screening frequency. Participants identified as having elevated or highest risk also received customized guidance on lowering their chances of developing breast cancer. This support system included access to an online decision-making tool focused on breast health and direct contact with a breast health specialist. Recommendations covered actionable lifestyle changes such as improving diet, increasing physical activity, and maintaining a healthy weight. Crucially, discussions also included the option of medications known to help reduce breast cancer risk, such as tamoxifen or raloxifene, which are typically considered for high-risk women. This holistic approach empowers women with knowledge and tools to actively participate in their breast health management.
Dr. Laura J. Esserman, MD, MBA, director of the UCSF Breast Care Center and the study’s first author, emphasized the transformative potential of these findings. "These findings should transform clinical guidelines for breast cancer screening and alter clinical practice," she stated. "The personalized approach begins with risk assessment, incorporating genetic, biological, and lifestyle factors, which can then guide effective prevention strategies." Her sentiment was echoed by co-author Dr. Jeffrey A. Tice, a UCSF professor of Medicine specializing in breast cancer risk assessment tools, who added, "Shifting resources from lower-risk women to higher-risk women is an efficient, effective approach to screening for and preventing breast cancer."
Broader Implications and the Path Forward
The implications of the WISDOM study are far-reaching, poised to impact not only individual patient care but also public health policy, healthcare economics, and the broader landscape of personalized medicine.
Impact on Clinical Guidelines and Healthcare Policy: The most immediate consequence will likely be a re-evaluation of national and international breast cancer screening guidelines. Major medical organizations, including the American Cancer Society, the American College of Radiology, and the USPSTF, will undoubtedly review these robust findings. The process of updating guidelines is often lengthy and involves consensus among experts, but the evidence presented by WISDOM is compelling enough to initiate serious consideration for incorporating comprehensive risk assessment into standard practice. This shift could lead to more nuanced recommendations that move away from rigid age brackets and towards individualized screening plans.
Resource Allocation and Economic Implications: Implementing a personalized screening strategy has significant economic ramifications. While initial concerns might arise about the cost of widespread genetic testing and more frequent MRI scans for high-risk individuals, the study suggests a potential for overall cost-effectiveness. By reducing unnecessary mammograms for lower-risk women and targeting intensive screening and prevention to those who need it most, healthcare systems could reallocate resources more efficiently. Reduced rates of advanced cancer diagnoses could also lead to substantial savings in treatment costs, which are significantly higher for late-stage cancers. Insurance providers would need to adapt coverage policies to support comprehensive risk assessment, including genetic testing and risk-reducing interventions, as standard components of breast health care.
Ethical Considerations and Equity: The transition to personalized screening also raises important ethical and equity considerations. Ensuring equitable access to advanced risk assessment tools, genetic testing, and subsequent tailored screening and prevention strategies will be paramount. Disparities in access based on socioeconomic status, geographic location, or racial and ethnic background could exacerbate existing health inequalities if not proactively addressed. Public education campaigns will be vital to inform women about the benefits of personalized screening and encourage participation in risk assessment programs.
Patient Empowerment and Shared Decision-Making: A personalized approach inherently empowers patients by providing them with a deeper understanding of their individual risk profile. This knowledge facilitates more informed discussions with healthcare providers and promotes shared decision-making regarding screening choices. The high acceptance rate of risk-based screening in the WISDOM observational group highlights patients’ readiness to embrace a more tailored approach to their health.
The Future of Personalized Medicine: The WISDOM study serves as a powerful testament to the potential of personalized medicine, not just in oncology but across various medical disciplines. By leveraging advances in genomics, data analytics, and risk modeling, healthcare is moving towards a future where prevention and treatment are precisely tailored to the individual.
Looking ahead, researchers are continuing to refine risk assessment through the WISDOM 2.0 study, which is actively enrolling participants. The ongoing goal is to enhance the ability to identify women at higher likelihood of developing aggressive breast cancers and to provide them with screening and prevention strategies that are optimally tailored to their long-term health needs.
Allison S. Fiscalini, MPH, of UCSF, director of the Athena Breast Health Network and the WISDOM study, underscored the profound impact. "This is one of the first studies to offer genetic testing to all women, regardless of family history," she noted. "When used as part of a comprehensive risk assessment, these results could have a real impact on improving the safety and effectiveness of screening and prevention."
The WISDOM study, supported by funding from organizations including the Patient-Centered Outcomes Research Institute, the National Cancer Institute, and the Breast Cancer Research Foundation, involved a collaborative effort across numerous institutions. Co-authors from UCSF included Laura J. van ‘t Veer, PhD; Maren T. Scheuner MD; Alexander D. Borowsky, MD; Amie M. Blanco, MD; Katherine S. Ross, MS; Barry S. Tong, MS; Diane Heditsian; Susie Brain; Vivian Lee; Kelly Blum, MS; Mi-Ok Kim, PhD; Leah P. Sabacan, MBA; Kirkpatrick B. Fergus, MD; Christina Yau, PhD; Celia Kaplan, DrPH; Suzanne Elder, CFNP; Kelly Adduci, MPH; Jeffrey B. Matthews, PhD; Robert A. Hiatt, MD, PhD; Elad Ziv, MD; and Jeffrey A. Tice, MD. Additional investigators contributed from UC Los Angeles, UC Irvine, UC San Diego, San Francisco VA Health Care System, Sanford Health in North Dakota, University of Chicago, Diagnostic Center of Miami, University of Alabama, Virginia Commonwealth University, Weill Cornell Medicine in New York, and the Karolinska Institutet in Stockholm. This extensive collaboration highlights the multidisciplinary and widespread commitment to advancing breast cancer screening.
The WISDOM study marks a pivotal moment in the fight against breast cancer, offering a data-driven blueprint for a more precise, equitable, and effective approach to screening that moves beyond the limitations of age and embraces the complexity of individual risk.
